The Cooper Companies, Inc.

The stock is in a recovery phase after a pullback from its 52-week high of 89.83, but it still trades below the 200-day average of 72.89. The 50-day average at 64.91 sits well below the 200-day line, pointing to a longer-term setup that is stabilizing but not yet fully repaired.

Street sentiment leans constructive, with a Buy consensus and an average target around 80.33 versus the current setup near the low-70s. Recent actions have been mostly reiterations and target cuts rather than rating downgrades, which suggests cautious optimism rather than a clean re-rating.

The earnings trend is strong: COO has beaten EPS estimates in 7 of 7 recent quarters, including an 11.0% beat in the latest reported quarter. Next-year EPS estimates are still rising, with the 2026 average at 4.62773 and 2027 at 5.00321, so shareholders should watch whether margin recovery keeps pace with that bar.

No notable discretionary insider buying or selling. The recent filings are dominated by award grants and exempt/vesting-related transactions for directors, which are routine compensation flows rather than a directional signal.

Profitability is mixed but improving at the top line: revenue grew 7.9% year over year and earnings grew 26.9%. Gross margin is a healthy 65.5%, though operating margin remains slightly negative at -2.87%, while free cash flow of $1.158 billion and an 8.40% FCF yield support the balance sheet story.

COO’s appeal is its premium gross margin profile and diversified exposure across contact lenses and women’s health. The stock still screens at a reasonable 15.65x earnings, below the market’s usual premium for durable healthcare franchises, while the analyst target range implies room for multiple expansion if execution holds.